REG - ReNeuron Group plc - Directors Share Purchases

ReNeuronAnnouncement

27/09/2018 15:05

RNS Number : 2127C
ReNeuron Group plc
27 September 2018
 


 




27 September 2018


AIM: RENE




 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Directors Share Purchases
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 27 September 2018 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by directors of the Company:
 




Name


Title


Number of Ordinary Shares purchased


Total beneficial interest in the Company's Ordinary Shares


Percentage of Company's Total Voting Rights




Olav Hellebø


Chief Executive Officer


14,936


21,630


0.068




Michael Hunt


Chief Financial Officer


7,462


27,546


0.087




 
ENQUIRIES:
 




ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer


 




Michael Hunt, Chief Financial Officer


 




Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Cowles, Tilly Abraham


 




 


 




Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)


 




 
About ReNeuron
 
ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  
 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.
 
 
 
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to purchase of Ordinary Shares)




 1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Olav Hellebo




2


Reason for the notification 




a)


Position/status 


Chief Executive Officer




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


N/A




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares 0.01p
 
RENE - GB00B0DZML60




b)


Nature of the transaction 


Purchase of ordinary shares




c)


Price(s) and volume(s)
 






 Price(s) 


Volume(s)




66.9p


14,936




 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


27 September 2018




f)


Place of the transaction 


London Stock Exchange, AIM Market




 




 1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Michael Hunt




2


Reason for the notification 




a)


Position/status 


Chief Financial Officer




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


N/A




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares 0.01p
 
RENE - GB00B0DZML60




b)


Nature of the transaction 


Purchase of ordinary shares




c)


Price(s) and volume(s)
 






 Price(s) 


Volume(s)




67p


7,462




 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


27 September 2018




f)


Place of the transaction 


London Stock Exchange, AIM Market




 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLLFEVATIDFIT